Surgery at primary versus relapsed epithelial ovarian cancer: a study on aspects of anaesthesiological management.
Feldheiser A1, Yosef AB2, Braicu EI3, Bonomo T4, Kaufner L2, Spies C2, Sehouli J3, Fotopoulou C5, Pietzner K3
Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
Gasimli K1, Braicu EI, Richter R, Chekerov R, Sehouli J.
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.
Okamoto A1, Sehouli J2, Yanaihara N1, Hirata Y1, Braicu I2, Kim BG3, Takakura S1, Saito M1, Yanagida S1, Takenaka M1, Yamaguchi N1, Morikawa A1, Tanabe H1, Yamada K1, Yoshihara K4, Enomoto T4, Itamochi H5, Kigawa J5, Matsumura N6, Konishi I6, Aida S7, Aoki Y8, Ishii N8, Ochiai K1, Akiyama T7, Urashima M9
Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors.
Vasconcelos I1, Olschewski J2, Braicu I2, Sehouli J2
A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants
Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma
Taube ET1, Denkert C, Pietzner K, Dietel M, Sehouli J, Darb-Esfahani S
Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors
Lazarou A1, Fotopoulou C2, Coumbos A3, Sehouli J4, Vasiljeva J5, Braicu I2, Burger H6, Kuehn W3
Surgical and systemic management of endometrial cancer: an international survey
Fotopoulou C1, Kraetschell R, Dowdy S, Fujiwara K, Yaegashi N, Larusso D, Casado A, Mahner S, Herzog TJ, Kehoe S, Vergote I, Miller DS, Marth C, Fujii S, Sehouli J
Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer
Despierre E1, Moisse M2, Yesilyurt B2, Sehouli J3, Braicu I3, Mahner S4, Castillo-Tong DC5, Zeillinger R5, Lambrechts S6, Leunen K6, Amant F6, Moerman P7, Lambrechts D8, Vergote I6
HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium
Braicu EI1, Luketina H1, Richter R1, Cacsire Castillo-Tong D2, Lambrechts S3, Mahner S4, Concin N5, Mentze M1, Zeillinger R6, Vergote I3, Sehouli J1
Identification of 34 N-glycan isomers in human serum by capillary electrophoresis coupled with laser-induced fluorescence allows improving glycan biomarker discovery
Schwedler C1, Kaup M, Weiz S, Hoppe M, Braicu EI, Sehouli J, Hoppe B, Tauber R, Berger M, Blanchard V
The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases
Biskup K1, Braicu EI2, Sehouli J2, Tauber R1, Blanchard V1
Polymorphism of the IL-8 gene and the risk of ovarian cancer
Koensgen D1, Bruennert D2, Ungureanu S3, Sofroni D4, Braicu EI5, Sehouli J6, Sümnig A7, Delogu S8, Zygmunt M9, Goyal P10, Evert M11, Olek S12, Biebler KE13, Mustea A14
Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
Woopen H1, Pietzner K1, Richter R1, Fotopoulou C1, Joens T2, Braicu EI1, Mellstedt H3, Mahner S4, Lindhofer H5, Darb-Esfahani S6, Denkert C6, Sehouli J1
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumor Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
Ruscito I1, Dimitrova D2, Vasconcelos I2, Gellhaus K3, Schwachula T3, Bellati F4, Zeillinger R5, Benedetti-Panici P4, Vergote I6, Mahner S7, Cacsire-Tong D3, Concin N8, Darb-Esfahani S9, Lambrechts S6, Sehouli J2, Olek S3, Braicu EI10
Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium
Braicu EI1, Van Gorp T2, Nassir M1, Richter R1, Chekerov R1, Gasimli K1, Timmerman D3, Vergote I3, Sehouli J1
Sialic acid methylation refines capillary electrophoresis laser-induced fluorescence analyses of immunoglobulin G N-glycans of ovarian cancer patients
Schwedler C, Kaup M, Petzold D, Hoppe B, Braicu EI, Sehouli J, Ehlers M, Berger M, Tauber R, Blanchard V
Impact of ascites on the perioperative course of patients with advanced ovarian cancer undergoing extensive cytoreduction: results of a study on 119 patients
Feldheiser A1, Braicu EI, Bonomo T, Walther A, Kaufner L, Pietzner K, Spies C, Sehouli J, Fotopoulou C
A case of primary peritoneal carcinoma: evidence for a precursor in the fallopian tube
Nasser S1, Arsenic R, Lohneis P, Kosian P, Sehouli J
ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer
Muallem MZ1, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R
Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-κB pathway
Darb-Esfahani S1, Sinn BV, Rudl M, Sehouli J, Braicu I, Dietel M, Denkert C
Synchronous ovarian and endometrial cancer--an international multicenter case-control study
Heitz F1, Amant F, Fotopoulou C, Battista MJ, Wimberger P, Traut A, Fisseler-Eckhoff A, Harter P, Vandenput I, Sehouli J, Schmidt M, Kimmig R, du Bois R, du Bois A
HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse
Braicu EI1, Chekerov R, Richter R, Pop C, Nassir M, Loefgren H, Stamatian F, Muallem MZ, Hall C, Fotopoulou C, Sehouli J, Pietzner K
Salvage surgery due to bowel obstruction in advanced or relapsed ovarian cancer resulting in short bowel syndrome and long-life total parenteral nutrition: surgical and clinical outcome
Fotopoulou C1, Braicu EI, Kwee SL, Kuhberg M, Richter R, Pietzner K, Feldheiser A, Bahra M, Schmidt SC, Sehouli J
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium
Pils D1, Bachmayr-Heyda A2, Auer K2, Svoboda M3, Auner V2, Hager G2, Obermayr E4, Reiner A5, Reinthaller A2, Speiser P2, Braicu I6, Sehouli J6, Lambrechts S7, Vergote I7, Mahner S8, Berger A9, Cacsire Castillo-Tong D2, Zeillinger R
Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube
Sehouli J1, Olschewski J, Schotters V, Fotopoulou C, Pietzner K
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
Türbachova I1, Schwachula T1, Vasconcelos I1, Mustea A2, Baldinger T1, Jones KA3, Bujard H4, Olek A5, Olek K6, Gellhaus K1, Braicu I7, Könsgen D2, Fryer C8, Ravot E9, Hellwag A1, Westerfeld N10, Gruss OJ11, Meissner M12, Hasan MT13, Weber M1, Hoffmüller U1, Zimmermann S1, Loddenkemper C14, Mahner S15, Babel N16, Berns E17, Adams R18, Zeilinger R19, Baron U1, Vergote I20, Maughan T21, Marme F22, Dickhaus T23, Sehouli J7, Olek S
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium
Bachmayr-Heyda A1, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC
Association of myeloperoxidase with ovarian cancer
Castillo-Tong DC1, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF
Serum glycome profiling: a biomarker for diagnosis of ovarian cancer
Biskup K1, Braicu EI, Sehouli J, Fotopoulou C, Tauber R, Berger M, Blanchard V
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
Trillsch F1, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R, Vergote I, Mahner S, Sehouli J
Alterations in expression pattern of splicing factors in epithelial ovarian cancer and its clinical impact
Iborra S1, Hirschfeld M, Jaeger M, Zur Hausen A, Braicu I, Sehouli J, Gitsch G, Stickeler E
Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer
Pietzner K1, Woopen H, Richter R, Joens T, Braicu EI, Dimitrova D, Mellstedt H, Darb-Esfahani S, Denkert C, Lindhofer H, Fotopoulou C, Sehouli J
Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential
Frede J1, Fraser SP, Oskay-Özcelik G, Hong Y, Ioana Braicu E, Sehouli J, Gabra H, Djamgoz MB
HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network
Nassir M1, Darb-Esfahani S, Richter R, Chekerov R, Hall C, Muallem MZ, Denkert C, Stamatian F, Fotopoulou C, Sehouli J, Braicu EI
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium
Pils D1, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer
Aust S1, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M, Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC
Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma
Liebscher CA1, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, Sehouli J, Braicu EI, Dietel M, Darb-Esfahani S
Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD
Chekerov R1, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J
Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
Fotopoulou C1, Savvatis K, Kosian P, Braicu IE, Papanikolaou G, Pietzner K, Schmidt SC, Sehouli J
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis
Serce NB1, Boesl A, Klaman I, von Serényi S, Noetzel E, Press MF, Dimmler A, Hartmann A, Sehouli J, Knuechel R, Beckmann MW, Fasching PA, Dahl E
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study
Braicu EI1, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J
Balanced crystalloid compared with balanced colloid solution using a goal-directed haemodynamic algorithm
Feldheiser A1, Pavlova V, Bonomo T, Jones A, Fotopoulou C, Sehouli J, Wernecke KD, Spies C
Methylation status of TUSC3 is a prognostic factor in ovarian cancer
Pils D1, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary
Bauerschlag D1, Bräutigam K, Moll R, Sehouli J, Mustea A, Salehin D, Krajewska M, Reed JC, Maass N, Hampton GM, Meinhold-Heerlein I
Endo-β-N-acetylglucosaminidase H de-N-glycosylation in a domestic microwave oven: application to biomarker discovery
Frisch E1, Schwedler C, Kaup M, Iona Braicu E, Gröne J, Lauscher JC, Sehouli J, Zimmermann M, Tauber R, Berger M, Blanchard V
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium
Melmer A1, Fineder L, Lamina C, Kollerits B, Dieplinger B, Braicu I, Sehouli J, Cadron I, Vergote I, Mahner S, Zeimet AG, Castillo-Tong DC, Ebenbichler CF, Zeillinger R, Dieplinger H
Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases
Neumann UP1, Fotopoulou C, Schmeding M, Thelen A, Papanikolaou G, Braicu EI, Neuhaus P, Sehouli J
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation
Fotopoulou C1, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium
Obermayr E1, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium
Aust S1, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, Vergote I, Speiser P, Horvat R, Zeillinger R, Pils D
Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma
Darb-Esfahani S1, Fritzsche F, Kristiansen G, Weichert W, Sehouli J, Braicu I, Dietel M, Denkert C
"IMO"--intraoperative mapping of ovarian cancer
Sehouli J1, Könsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, Lichtenegger W
